Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05372120 Recruiting - Clinical trials for Advanced Solid Tumor

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Start date: December 15, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II clinical trial in treated patients with advanced solid tumors with FGF/FGFR gene alterations. The purpose of this study is to evaluate the efficacy and safety of ICP-192.

NCT ID: NCT05367778 Recruiting - Clinical trials for Advanced Solid Tumor

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

Start date: June 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.

NCT ID: NCT05354843 Recruiting - Clinical trials for Advanced Solid Tumor

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

Start date: October 27, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors. It is anticipated that approximately 37 subjects will be enrolled in the dose-escalation phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.

NCT ID: NCT05352750 Recruiting - Clinical trials for Advanced Solid Tumor

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

Start date: April 20, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.

NCT ID: NCT05346484 Recruiting - Solid Tumor Clinical Trials

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

MAST
Start date: May 17, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.

NCT ID: NCT05341570 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668

Start date: January 19, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-21668 in solid tumor patients. In dose escalation phase, biomarker status is not required, but in dose expansion phase patients are required to harbor PIK3CA mutation.

NCT ID: NCT05329103 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Start date: July 11, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.

NCT ID: NCT05320588 Recruiting - Cancer Clinical Trials

A Study in Patients With Advanced Cancers

Start date: March 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.

NCT ID: NCT05318573 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced solid tumors.

NCT ID: NCT05315167 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Start date: May 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.